Dry Mouth: As is the case with many other hemp- and marijuana-based products, CBD oil often leads to a condition known as dry mouth (or cottonmouth). This is likely due to cannabinoids altering receptors in the lower jaw that trigger salivation. In most cases, mild discomfort and stronger-than-average thirst are the only issues associated with dry mouth.
Cannabidiol, or CBD for short, is a phyto-cannabinoid found in cannabis plants. However, it does not cause the same psychoactive effects as other naturally occurring cannabinoids (such as tetrahydrocannabinol, or THC). CBD induces feelings of sleepiness and tranquility, making it suitable for insomnia and other sleep disorders; CBD can be used to alleviate symptoms of epilepsy, diabetes, and anxiety disorders, as well. Legality is an issue for some; all 50 states have laws governing the sale, possession, and use of CBD, and they vary significantly (see the table below for a full analysis).
CBD oil products can be somewhat expensive, which may be a barrier for individuals seeking treatment or relief from different conditions and disorders. Right alongside price comes taste and a lot of consumer don’t like the earthy flavor of hemp. cbdMD is here to help on both fronts with a wide range of flavors that actually taste good at a price consumers can afford. cbdMD offers it’s premium, non-THC oils at a large variety of concentrations (300mg-5,00mg) as well as sizes (30mL and 60mL) . These oils are priced at $28 for 300mg oils and $90 for 1,500mg oils; both price-points are significantly below average.
NuRyse Hemp Oil Extract 1000mg includes a 1-year money back guarantee, which is unique when compared to other hemp oil products on the market. In addition, NuRyse Hemp Oil Extract is made in the USA, is flavored and formulated with all-natural ingredients, and is available in varying levels of potency (250mg and 500mg in addition to the 1000mg bottle). It is a hemp seed oil product, however, so it will not contain the CBD cannabinoid. Each bottle contains the standard 30-day supply with recommended dosage.
Cunha et al. reported a 2-phase pilot study of CBD versus placebo in normal volunteers and patients with refractory secondarily generalized epilepsy (14). In the first phase, 8 normal volunteers received CBD or placebo in a doubled-blind fashion, at a dose of 3 mg/kg for 30 days. The second phase was also double-blinded in 15 patients with epilepsy receiving 200 to 300 mg daily of CBD or placebo for 135 days. Patients continued baseline AED. All subjects tolerated CBD well, with no serious adverse events. Four of the epilepsy patients receiving CBD were “almost free of convulsive crisis” for the duration of the study. Three other patients receiving CBD had a partial reduction in seizures, and 1 subject had no response. Of the 7 patients receiving placebo, seizure frequency was unchanged in 6, and 1 had clear improvement in seizure control.